Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's EBITDA?
- Protagonist Therapeutics (PTGX) reported EBITDA of $159.16M in Q2 2026.
- How has Protagonist Therapeutics's EBITDA changed year-over-year?
- Protagonist Therapeutics's EBITDA increased by 481.3% year-over-year, from -$41.74M to $159.16M.
- What is the long-term trend for Protagonist Therapeutics's EBITDA?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's EBITDA has grown at a 7.8% compound annual growth rate (CAGR), from -$125.03M to -$156.85M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Protagonist Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude